Evidence map›Paper›PMID 39480886›Full record

ArticlePLoS pathogens2024

B cell receptor dependent enhancement of dengue virus infection.

Chad Gebo, Céline S C Hardy, Benjamin D McElvany, Nancy R Graham, Joseph Q Lu, Shima Moradpour, Jeffrey R Currier, Heather Friberg, Gregory D Gromowski, Stephen J Thomas and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.Current topics in microbiology and immunology · 2026
    Review
  10. Dengue and severe dengue.Clinical microbiology reviews · 2025
    Review
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Chad GeboDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of America.
Céline S C HardyDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of America.
Benjamin D McElvanyDepartment of Microbiology and Molecular Genetics, The University of Vermont Larner College of Medicine, Vaccine Testing Center, Burlington, Vermont, United States of America.
Nancy R GrahamDepartment of Microbiology and Molecular Genetics, The University of Vermont Larner College of Medicine, Vaccine Testing Center, Burlington, Vermont, United States of America.
Joseph Q LuDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of America.
Shima MoradpourDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of America.
Jeffrey R CurrierViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Heather FribergViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Gregory D GromowskiViral Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, United States of America.
Stephen J ThomasDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of America.
Gary C ChanDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of America.
Sean A DiehlDepartment of Microbiology and Molecular Genetics, The University of Vermont Larner College of Medicine, Vaccine Testing Center, Burlington, Vermont, United States of America.
Adam T WaickmanDepartment of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, New York, United States of America.ORCID 0000-0002-4536-6714

Funding

Using Dengue Controlled Human Infection Model to Identify Adaptive Immune Correlates of ProtectionP20GM125498 · NIGMS · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Ellen Kozelka · 2018 to 2026
$24.9M
Mechanisms of Protection and Durability for a Live Attenuated Tetravalent Dengue VaccineU01AI141997 · NIAID · UNIVERSITY OF VERMONT & ST AGRIC COLLEGE · PI Sean A. Diehl, Anna Palmer Durbin · 2019 to 2026
$5.1M
NIAID NIH HHS U01 AI141997NIGMS NIH HHS P20 GM125498
6 · The paper itself

Abstract

Dengue virus (DENV) is the causative agent of dengue, a mosquito-borne disease that represents a significant and growing public health burden around the world. A unique pathophysiological feature of dengue is immune-mediated enhancement, wherein preexisting immunity elicited by a primary infection can enhance the severity of a subsequent infection by a heterologous DENV serotype. A leading mechanistic explanation for this phenomenon is antibody dependent enhancement (ADE), where sub-neutralizing concentrations of DENV-specific IgG antibodies facilitate entry of DENV into FcγR expressing cells such as monocytes, macrophages, and dendritic cells. Accordingly, this model posits that phagocytic mononuclear cells are the primary reservoir of DENV. However, analysis of samples from individuals experiencing acute DENV infection reveals that B cells are the largest reservoir of infected circulating cells, representing a disconnect in our understanding of immune-mediated DENV tropism. In this study, we demonstrate that the expression of a DENV-specific B cell receptor (BCR) renders cells highly susceptible to DENV infection, with the infection-enhancing activity of the membrane-restricted BCR correlating with the ADE potential of the IgG version of the antibody. In addition, we observed that the frequency of DENV-infectible B cells increases in previously flavivirus-naïve volunteers after a primary DENV infection. These findings suggest that BCR-dependent infection of B cells is a novel mechanism immune-mediated enhancement of DENV-infection.

Indexed as

Antibody-Dependent EnhancementB-LymphocytesDengueDengue VirusReceptors, Antigen, B-CellAnimalsAntibodies, NeutralizingAntibodies, ViralHumansImmunoglobulin GAntibodies, NeutralizingAntibodies, ViralImmunoglobulin GReceptors, Antigen, B-Cell

Identifiers

PMID39480886
PMCPMC11556684

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.